MCLA-145 is under clinical development by Merus and currently in Phase I for Oral Cavity (Mouth) Cancer. According to GlobalData, Phase I drugs for Oral Cavity (Mouth) Cancer does not have sufficient ...

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Oral Cavity (Mouth) Cancer.

Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...

Medically reviewed by William Truswell, MD Lip cancer is an oral cancer that first develops on the lips, usually causing an ...

GORTEC is a cooperative group dedicated to Head and Neck Oncology. GORTEC has a long-standing experience of large scale international innovative phase III trials relying on a robust high-quality study ...

The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck squamous cell carcinoma undergoing radiotherapy with contraindications to ...

Those who use tobacco products are at 10 times greater risk of developing a head and neck squamous cell carcinoma ... with a 25 percent drop in cancer of the oral cavity. Tea was linked with ...